of gynaecological oncology
an International Journal
San Diego - CA (USA)
Publishing Organization (M. Morsani):
|Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Barber H.K., New York, NY (USA)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Fuller A.F. Jr., Boston, MA (USA)
|Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M., Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,Athens (Greece)
Jordan J.A., Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Kudelka A.P., Houston, TX (USA)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H., London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Vîrtej P., Bucharest (Romania)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan)
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal,
Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: email@example.com
Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 -
Fax (39) 049 8752018
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN
0392-2936) publishes original peer reviewed works in the fields of female
genital cancers and related subjects and also proceedings of gynecologic
oncology society meetings all over the world. The Journal is covered by
CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/
Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.
European Journal of Gynaecological
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936)
publishes original peer reviewed work, preferably brief reports, in the
fields of female genital cancers and related subjects – prevention,
early detection, epidemiology, pathology, diagnosis, management –
and also proceedings of Gynaecologic Oncology Society meetings all over
The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT,
INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.
AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing
editorial articles in the “Distin-guished Expert Series” and
original research papers, case reports, letters to the Editor, book reviews
The Journal was founded in 1980 – the second gynaecologic oncology
hyperspecialization journal in the world. Its aim is the dif-fusion of
scientific, clinical and practical progress and knowledge in female neoplastic
diseases in an interdisciplinary approach among gynaecologists, oncologists,
radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists
and so on.
ANNOUNCEMENTS regarding meetings, postgraduate courses
and symposia will be accepted 6 months before publication and will be
published free of charge.
BOOK SAMPLES for review should be sent to the Editorial
offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright
Clearance Center, Inc. Reproductions are not allowed without the written
consent of the Publisher. All photocopy fees should be paid to the Copyright
Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating
the ISSN number, the volume and the first and last page numbers of each
ADVERTISING INFORMATION: advertising orders and inquiries
may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc,
Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640
- Fax 514.4854513 - E-mail: firstname.lastname@example.org - www.irog.net
RESPONSIBILITY: although every effort is made by the
editorial staff and the printer to eliminate misleading or inaccurate
infor-mation, the publisher accepts no responsibility for the consequences
of faultful or incorrect information. The authors recognize that the editor
and publisher have no responsibility and are indemnified against any liability
or claim that may result from the publication of misleading or incorrect
The Journal is published bimonthly (January, March, May, July, September
and November); one volume per year. Subscriptions start from January and
are automatically renewed if not cancelled by the end of September.
Subscriptions include six issues per year plus supplements, monographs
and all official communications of Meetings, Courses, Symposia and all
scientific activities of Gynaecologic Oncology Societies all over the
Subscriptions are entered with prepayment only. The annual
subscription is $390 US for Institutions, $200 US for Individuals. For
airmail add $30, for receipt add $10 US. Single copy prepaid cost $95
Send subscription requests with cheque or credit card payment (Amex -
Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte
St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only
US Funds are accepted. No bank transfers.
Claims for missing issues can be honoured up to six months.
Changes of address: allow six weeks for all changes to
become effec-tive. All communications should include both old and new
addresses (with postal codes) – better if accompanied by a mailing
label from a recent issue – and should be sent to the printer: La
Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580.
Claims should be made within six months of publication date.
Duplicate copies will not be sent to replace those undelivered through
failure to notify of change of address.
Single copies and back issue and volume information is available from
the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580.
Certain back issues may only be available as photocopies of the originals.
All other business correspondence including orders for offprints and advertising
space and any communication and requests should be addressed to I.R.O.G.
CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC
H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.
IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT
European Journal of Gynaecological
Instructions to Authors
SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN
JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212
MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513,
or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.
Editorial articles for publication in the “Distinguished Expert
Series” should be submitted to P. Bösze, Editor-in-Chief of
this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest,
Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: email@example.com
When a manuscript is submitted, an acknowledgement card is sent to the
corresponding author within two or three weeks.
Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees.
Authors may be required to modify the manuscript according to the reviewers’
Manuscripts accepted for publication will be copyedited by the editorial
staff for typographical and grammatical mistakes and to guarantee clarity
Publication time will be the shortest possible based
on scientific and publishing needs. Manuscripts submitted for
publi-cation cannot be returned.
Published papers will become property of the Journal and copyrighted under
I.R.O.G. CANADA Inc.
After six months no grievances will be accepted regarding published articles.
All statements are the responsibility of the authors. Product dosages,
indications and methods referred to in the papers reflect the author’s
experience. No responsibility is assumed by the Editor-in-Chief or the
Publisher for any damage from use of any products, operation methods or
instructions contained in the published materials.
Trade names, trademarks, etc. are protected by the law and regulations.
The Editor-in-Chief and the Publisher cannot accept any legal responsibility
for any errors or omissions that may be made in press, particularly for
information about drug dosage and appli-cation thereof contained in the
Journal. Consult the prescribing information before administering any
The Journal follows the “Uniform requirements for manuscripts submitted
to biomedical journals” published in the New England Journal of
Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.
Three manuscripts, typed and double spaced should be
submitted with an electronic disk, formatted in Word for Macintosh
or Windows, version 6.0. Manuscripts without an electronic disk
will not be accepted. A cover letter signed by all authors must
state that all authors who have participated in the work take responsibility
for the manuscript which has never been pub lished or submitted for publication
elsewhere. Without a cover letter the publication will not be
possible. Name, address and phone/fax numbers of the Corresponding Author,
responsible for revision and approval of the proofs, should be indicated.
Full-length articles should not exceed 8 printed pages including tables
After the title page (full title and names of authors,
institutions, eventual acknowledgement for financial support, running
title of no more than 60 characters or spaces), original works should
be arranged in the conventional order: Summary (purpose of investiga-tion,
methods, results, conclusion - about 150 words), Key words, Content
(a 20-word summary), Introduction, Materials and Methods, Results,
Discussion, Conclusion, Acknowledgement (if any), References, Tables,
Authors should supply a complete address for reprint requests.
In the text only standard abbreviations can be used and must be avoided
in the title. The full term for which an abbreviation stands should precede
its first use in the summary and text unless it is a standard unit of
Authors must give their complete professional identifications
and affiliations, including all academic titles and positions.
Letters to the editor should be brief (500 words or less)
and offer objective, constructive and educational criticism of published
material. The editor reserves the right to publish.
Figures: Two original copies (not negatives) of each
figure are requested. Each figure should have a label on the back indicating
its number, author’s name and top of the figure. Do not write on
the back of the figures and do not mount them on cardboard. If
sending colour pictures advise if they must be printed in colour or black
and white (colour costs ten times more).
Legends should be typed on a separate page with Arabic
numerals corresponding to the illustrations.
Tables should be titled, typed in double space on separate
pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood
abbreviations should be used.
References should be numbered consecutively in the order in which
they are first mentioned in the text. Identify references in
the text, tables, and legends by Arabic numerals in parentheses.
Use the style of the examples below, which are based with slight modifications
on the format used by the U.S. National Library of Medicine in Index Medicus.
The titles of journals should be abbreviated according to the style used
in Index Medicus.
References must be verified by the Author(s) against the original documents.
Examples of correct forms of references are given below:
Articles in Journals: Authors’ surname and initials
(if more than six names, give six followed by “et al.”), Title,
Abbreviated Journal Title, Year of Publication, Volume, Issue and first
Books: Authors’ surname and initials, title of
the book and title of chapter, in: Title, Editor(s), Place, Publisher,
Acknowledgments will be limited to appropriate professionals
who were contributors to the paper.
PROOFS revised by the editorial staff will
be sent to the corresponding author and should be checked and returned
within ten days. The corresponding author is responsible for detecting
typesetting errors. After this deadline the proofs will be considered
approved. Only essential corrections should be made; extensive changes
will be charged to the authors.
The Journal has no commercial advertisements.
Authors will be expected to contribute to the printing expenses,
tables, figures and postage. For every published article a copy
of the Journal will be provided free of charge. Only payments
in US dollars will be accepted. No bank transfers.
Reprints should be requested with the form enclosed
with the acceptance letter. No free reprints will be supplied.
© By I.R.O.G. CANADA INC. - Publisher - Editorial office
4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3
(Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy
by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy)
- Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s
Court n. 633 - 28-6-1979
European Journal of Gynaecological Oncology - Vol. XXIX, n. 3, 2008
|DISTINGUISHED EXPERT SERIES
|New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors
|K. Syrjänen - Turku, FINLAND
Novel observations on risk factors that are still controversial (i.e., oral contraception, smoking) or not previously studied (drug
addiction), reproductive factors as potential cofactors of HPV infections in cervical carcinogenesis (i.e., menarche, menopause), and finally on the performance of different optional screening strategies among younger and older women are discussed.
|Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical
carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501) - initial
|Y. Niibe, S. Tsunoda, T. Jobo, M. Imai, K. Matsuo, K. Matsunaga, N. Unno, K. Hayakawa - Nagoya, JAPAN
The phase II study of concurrent chemoradiotherapy using nedaplatin for LAUCC is reported.
|Resource use and cost analysis of managing abnormal Pap smears: a retrospective study in five countries
|B. Rash, P. Martin-Hirsch, A. Schneider, M. Sideri, J. Tan, A. Torné, B. Standaert - Rixensart, BELGIUM
Resource use and costs associated with the management of abnormal pap smears vary between countries, depending on the
screening programme and the histological type.
|Discovery of altered protein profiles in epithelial ovarian carcinogenesis by SELDI mass spectrometry
|J. Luo, J.H. Qian, J.K. Yu, S. Zheng, X. Xie, W.G. Lu - Hangzhou, CHINA
The combination of SELDI and laser capture microdissection (LCM) is effective in finding the key molecules in ovarian
|Sentinel lymph nodes in endometrial cancer: is hysteroscopic injection valid?
|D. Clement, A.S. Bats, N. Ghazzar-Pierquet, M.A. Le Frere Belda, F. Larousserie, C. Nos, F. Lecuru - Paris,
Hysteroscopic peritumoral radiotracer injection for detecting sentinel lymph nodes (SLNs) in patients with endometrial cancer is
described together with the evaluation of the resulting SLN detection rate.
|Interval debulking in epithelial ovarian carcinomas: the past, present and the future
|M. Gultekin, K. Diribas, E. Buru, P. Dursun, K. Yuce, A. Ayhan - Ankara, TURKEY
The approach to interval debulking surgery in ovarian carcer is discussed in relation to neo-adjuvant chemotherapy and compared
with the literature data.
|Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect
extra-pelvic recurrence in uterine sarcomas
|P.L. Sung,Y.J. Chen, R.S. Liu, H.J. Shieh, P.H. Wang, M.S. Yen, K.C. Wen, S.H. Shen, C.R. Lai, C.C. Yuan -
The use of F-18-fluorodeoxyglucose positron emission tomography (18-FDG PET) for post-therapy surveillance of uterine sarcoma
|Clinical implication of medroxyprogesterone acetate against advanced ovarian carcinoma: a pilot study
|K. Niwa, K. Onogi,Y.Wu, H. Mori, R.C. Harrigan, T. Tamaya - Gifu-city, USA
MPA with chemotherapy might improve the prognosis of advanced epithelial ovarian cancers.
|Synchronous ovarian and endometrial carcinoma: a strong link to endometriosis?
|A. Kondi-Pafiti, D. Grapsa, A. Liapis, K. Papadias, E. Kairi-Vassilatou, D. Hasiakos - Athens, GREECE
A clinicopathological study of synchronous ovarian and endometrial carcinomas reveals a strong link to endometriosis.
|Prognostic factors in patients with carcinoma of the vulva - our own experience and literature review
|P. Blecharz, K. Karolewski, T. Bieda, M. Klimek, J. Pudelek, E. Kojs, K. Zur, P. Dzialak, K. Urbanski -
Evaluation of prognostic factors and treatment outcomes in patients with vulvar cancer are examined.
|KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature
|M. Zafrakas, T.D. Theodoridis, L. Zepiridis, I.D. Venizelos, T. Agorastos, J. Bontis - Thessaloniki, GREECE
KIT expression was analyzed immunohistochemically in primary uterine sarcomas and was found to be very weak in the
majority of tumors.
|Cl-channel blockers inhibit cell proliferation and arrest the cell cycle of human ovarian cancer cells
|M. Li, B. Wang,W. Lin - Jinan, CHINA
The role of chloride channels in cell proliferation and cell cycles of human ovarian cancer cell A2780 was investigated.
|Cervical cancer associated with genital prolapse - a brief review of the literature and long-term results
of successful treatment with radiochemotherapy and surgery in a very frail patient
|D. Reimer, A. Sztankay, I. Steppan, E. Abfalter, H. Lunzer, C. Marth, A.G. Zeimet - Innsbruck, AUSTRIA
Successful treatment of cervical cancer associated with procidentia by external brachytherapy and extracorporeal HDR-AL
with concomitant chemotherapy followed by surgery.
|Stage 1B cervical cancer in a pregnant woman at 25 weeks of gestation
|E. González Bosquet, A. Castillo, M. Medina, M. Suñol, A. Capdevila, J.M. Lailla - Barcelona, SPAIN
A case of a 28-year-old pregnant woman diagnosed with Stage 1B cervical cancer is described.
|The role of ovarian transposition in patients with early stage cervical cancer - two case reports
|N. Salakos, K. Bakalianou, C. Iavazzo, G. Paltoglou, K. Papadias, A. Liapis, A. Kondi-Pafiti - Athens, GREECE
The role of ovarian transposition in patients with early-stage cervical cancer is examined.
|Squamous cell carcinoma arising in a mature cystic teratoma of the ovary in young patient with elevated
carbohydrate antigen 19-9
|D.T. Arioz, C. Tokyol, F.K. Sahin, G. Koker, S. Yilmaz, M. Yilmazer, S. Ozalp - Eskisehir, TURKEY
A very rare case of squamous cell carcinoma arising in a mature cystic teratoma in a 31-year-old single woman with very high
levels of CA19-9 and normal levels of CEA is presented.
|Primary vaginal melanoma: a case report and literature review
|M. Schmidt, A. Honig, M. Schwab, P. Adam, J. Dietl - Wuerzburg, GERMANY
Vaginal melanoma is a rare malignancy. Among different treatment options only wide local excision is associated with prolonged
|Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian
cancer: case report and literature review
|C.J. Ma, S.F. Yang, C.C. Huang, C.Y. Chai, K.I. Cheng, E.M. Tsai, J.Y. Wang - Kaohsiung, TAIWAN
Extragenital MMMTs are rare and may be associated with synchronous gastrointestinal or gynecological malignancies.
|Pelvic actinomycosis mimicking ovarian malignancy: three cases
|S.E. Akhan,Y. Dogan, S. Akhan, A.C. Iyibozkurt, S. Topuz, O. Yalcin - Istanbul, TURKEY
Three cases of pelvic actinomycosis mimicking ovarian cancer are described. All cases had a history of IUD use.
|A case of endometrial carcinoma arising in a 36-year-old woman with uterine atypical polypoid adenomyoma
|K. Bakalianou, N. Salakos, C. Iavazzo, G. Paltoglou, K. Papadias, A. Kondi-Pafiti - Athens, GREECE
A case of endometrial carcinoma arising in a 36-year-old woman with atypical polypoid adenomyoma is presented.
|Immature teratoma in pregnancy: a case report and literature review
|A. Daponte, E. Kostopoulou, A. Zavos, H. Skentou, A. Kallitsaris, G. Koukoulis, I.E. Messinis - Larissa,
An immature Stage I teratoma was removed during pregnancy. Appropriate surgical staging enabled avoidance of chemotherapy
despite the unexpected histological diagnosis.